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Abstract
Background: The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin 1 (mTORC1) signaling
pathway is aberrantly activated in renal cell carcinoma (RCC). We previously demonstrated glycogen synthase
kinase-3β (GSK-3β) positively regulated RCC proliferation. The aim of this study was to evaluate the role of GSK-3 in
the PI3K/Akt/mTORC1 pathway and regulation of the downstream substrates, eukaryotic translation initiation factor
4E-binding protein 1 (4EBP1), ribosomal protein S6 kinase (S6K), and ribosomal protein S6 (S6RP).
Methods: We used human RCC cell lines (ACHN, Caki1, and A498) and, as normal controls, human renal proximal
tubular epithelial cell (HRPTEpC) and non-tumorous kidney tissues that were obtained surgically for treatment of
RCC patients. Rapamycin-resistant ACHN (ACHN/RR) cells were generated with chronic exposure of ACHN to
rapamycin ranging from 1nM finally to 1 μM. Cell viability, cell cycling and direct interaction between GSK-3β and
4EBP1 were evaluated with MTS assay, flowcytometry and in vitro kinase assay with recombinant GSK-3β and
4EBP1products, respectively. Protein expression and phosphorylation of molecules associated with the
PI3K/Akt/mTORC1 pathway were examined by immunoblotting. Effects of drug combination were determined as
the combination index with CompuSyn software.
Results: Overexpression and phosphorylation of 4EBP1 and S6RP together with GSK-3 activation were observed in
RCC cell lines, but not in human normal kidney cells and tissues. Cell proliferation, p4EBP1 and pS6RP were strongly
suppressed by GSK-3 inhibition. Rapamycin and LY294002 sufficiently decreased pS6RP, but only moderately
p4EBP1. In vitro kinase assays showed that recombinant GSK-3β phosphorylated recombinant 4EBP1, and the effect
was blocked by GSK-3 inhibitors. Different from rapamycin, AR- A014418 remarkably inhibited cell proliferation, and
rapidly suppressed p4EBP1 and pS6RP in ACHN and ACHN/RR (in 30 min to 1 h). AR- A014418 and rapamycin
combination showed additivity at lower concentrations, but antagonism at higher concentrations.
Conclusions: GSK-3β could directly phosphorylate 4EBP1 and activate the mTORC1 downstream signaling cascades
to enhance protein biosynthesis and cell proliferation in RCC cell lines independent of rapamycin sensitivity. The
direct GSK-3β/4EBP1 pathway might be an important subcellular mechanism as an inherent equipment for RCC
cells to acquire clinical chemoresistance to mTORC1 inhibitors.
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Background
Renal cell carcinoma (RCC) is the most frequent form of
kidney cancer, accounting for up to 85 % of all cases [1].
Approximately 25–30 % of patients have metastatic RCC
(mRCC) at initial diagnosis [1]. The survival of patients
with mRCC has recently prolonged drastically, owing to
the development of novel targeted drugs [2]. In most
cases, tyrosine kinase inhibitors (TKIs) targeting vascular
endothelial growth factor are preferably administered as
the first-line drugs for treating mRCC [2, 3]. Two rapa-
logues that inhibit mammalian target of rapamycin com-
plex 1 (mTORC1), everolimus and temsirolimus, have
also been introduced in clinical practice for treating pa-
tients with mRCC [2, 3]. However, it is still extremely
rare to achieve a complete response with these drugs [2,
4]. Patients with mRCC succumb to the disease once
they lapse into refractory status. Thus, further improve-
ment of the therapeutic modality is warranted.
The phosphoinositide 3-kinase (PI3K)/Akt/mTORC1
signaling pathway is an important regulator of cell
growth, cell cycling, cell proliferation, metabolism, apop-
tosis, autophagy, and angiogenesis [5, 6], and is fre-
quently activated in a wide variety of cancers, including
RCC [5, 7]. mTORC1 controls these numerous cellular
functions mainly via the best-characterized substrates
ribosomal protein S6 kinase (S6K) and eukaryotic trans-
lation initiation factor 4E (eIF4E)-binding protein 1
(4EBP1) [5, 6]. S6K and 4EBP1 collaborate to play a role
in 5′ cap-dependent mRNA translation [6]. S6K stimu-
lates protein synthesis and cell growth, whereas 4EBP1
plays a predominant role in cell proliferation [8]. Experi-
ments involving inhibition of mTORC1 with rapamycin
have revealed the differential regulation between its two
downstream substrates, S6K and 4EBP1, in a cell type-
specific manner [9]. Furthermore, recent reports have
suggested that 4EBP1 phosphorylation is directly corre-
lated with the malignancy and severity of various tu-
mors, including RCC [10, 11]. Although mTORC1
seems to be the chief phosphorylation pathway of
4EBP1, other unidentified kinases and biochemical
mechanisms are also involved such as cyclin-dependent
kinase 1, ataxia-telangiectasia mutated/p53, RAS/extra-
cellular signal-regulated kinase1/2 and other collateral
signaling pathways [10, 12]. This is because multiple
phosphorylation sites in 4EBP1 can be partially insensi-
tive to rapamycin [10, 12–15]. It is well-known that the
mTOR pathway is also an important regulator of hyp-
oxia inducible factor, an essential driver of clear cell
RCC due to disruption of the von Hippel Lindau (VHL)
tumor suppressor gene, the somatic mutation of which
is the most frequent genetic alternation observed in
RCC [16].
Glycogen synthase kinase-3 (GSK-3) is a ubiquitously
expressed Ser/Thr kinase that regulates cellular function
via several mechanisms, including Wnt/β-catenin and
Hedgehog signal transduction, protein synthesis, glyco-
gen metabolism, mitosis, and apoptosis [17–19]. GSK-3
has two closely related isoforms, GSK-3α and GSK-3β,
which exhibit 97 % sequence identity within their cata-
lytic domains [17, 19]. GSK-3 can act as a tumor sup-
pressor or it can promote cell proliferation in different
types of cancers [17–19]. We previously demonstrated
that GSK-3β positively regulates the proliferation, sur-
vival, and anti-apoptosis mechanisms of cancer cells
through decreased expression of the nuclear factor-
kappa B target genes BCL-2 and X-linked inhibitor of
apoptosis protein (XIAP) [18, 20], and that nuclear accu-
mulation of GSK-3β could be a novel biomarker of blad-
der cancer [18] and RCC [20]. Furthermore, we
demonstrated that nuclear overexpression of GSK-3β
and tumor proliferation in RCC are negatively regulated
by miR-199, the only microRNA known to target GSK-
3β [21]. Moreover, pharmacological inhibition of GSK-3
was found to potentiate the anti-tumorous efficacy of
sorafenib, a TKI that is used for systemic therapy of
mRCC [22].
In the present study, we investigated direct relation-
ships between GSK-3β and 4EBP1 using human RCC
cell lines and a normal renal tubular epithelial cell line,
and normal renal tissues obtained from RCC patients
who had surgical resection, in order to study the role of
GSK-3 in the Akt/mTORC1/4EBP1 pathway in RCC.
Methods
Cell culture and reagents
The RCC cell lines ACHN, Caki1, and A498 were obtained
from American Type Culture Collection (Manassas, VA,
USA). ACHN is derived from pleural effusion in metastatic
RCC having wild type of VHL [23, 24]. Caki1 and A498
cells come from clear cell RCC with VHL wild type [23,
25], and clear cell RCC with VHL mutation (426_429delT-
GAC) [25], respectively. Cells were cultured in RPMI
medium supplemented with 50 μg/mL of kanamycin and
10 % fetal bovine serum in an incubator at 5 % CO2 and
37 °C. Human renal proximal tubular epithelial cell
(HRPTEpC) was obtained from Cell applications Inc (San
Diego, CA, USA). Cells were cultured in RenaEpi cell
growth medium with growth supplements in an incubator
at 5 % CO2 and 37 °C. AR-A014418 was purchased from
Calbiochem (San Diego, CA, USA). Two other GSK-3 in-
hibitors, SB-216763 and TDZD8, were obtained from Cay-
man Chemicals (Ann Arbor, MI, USA) and Sigma-Aldrich
Japan (Tokyo, Japan), respectively. Rapamycin and everoli-
mus were obtained from Selleck Chemicals (Houston, TX,
USA), LY294002 was from Wako Pure Chemical Industries
(Tokyo, Japan), recombinant GSK-3β was purchased from
New England Biolabs (NEB) Japan (Tokyo, Japan), and
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recombinant GST-4EBP1 was obtained from Sigma-
Aldrich Japan.
Induction of rapamycin-resistant renal cancer cell lines
The RCC cell line ACHN was cultured in progressively
increasing dose of rapamycin until sustained growth,
used concentration ranging from 1nM finally to 1 μM (for
approximately 4 months). Before use the rapamaycin-
resistant cells to investigate drug effects, the cells were
cultured in RPMI medium without rapamycin for five
passages.
siRNA transfection
For GSK-3β or GSK-3α silencing, ACHN cells were
transfected with specific human siRNAs against GSK3β
(25 μM or 50 μM) or GSK3α (50 μM) by using Lipofec-
tamine RNAiMAX (Invitrogen, Thermo Fisher Scientific
Inc. Yokohama, Japan) according to the manufacture’s
recommendations. Targeting sequences of siRNA are as
follows: GSK-3β; 5′-GGACAAGAGAUUUAAGAAUtt-
3′(Applied BioSystems, Thermo Fisher Scientific Inc.),
GSK-3α (siE523); 5′-GUCCUCACAAGCUUUAACUtt-
3′; GSK-3α (siE524); 5′-GUCUUAGUUUCCACAGUA
Att-3′ (TaKaRa Bio Inc., Shiga, Japan). Non-specific con-
trol siRNA (Applied BioSystems) was used as negative
control.
Preparation of normal human kidney tissues
Fresh frozen tissue samples obtained from three patients
with RCC who underwent nephrectomy at Yamagata
University Hospital were used in the present study. The
samples cut from the non-tumorous renal parenchyma
away from RCC areas were freshly frozen and maintained
at −80 °C until the experiments. The study was approved
by the Ethics Committee of Yamagata University Faculty
of Medicine (approval no. 55, 2015), and all patients
signed an informed consent form.
Immunoblot analysis
Immunoblot analysis was performed as described previ-
ously [22], using SuperSignal West Pico Substrate
(Pierce, Rockford, IL, USA) and Western BLoT Hyper
HRP Substrate (Takara Bio Inc) according to the manu-
facturers’ instructions. The images were analyzed using
UN-SCAN-Itgel Automated Digitizing System software
(Version 5.1 for Windows, Silk Scientific Inc., Orem,
UT, USA). The antibodies to the following chemicals
were used: 4EBP1, p4EBP1 (The70, Thr37/46, and
Ser65), S6K, pS6K (Ser371), ribosomal protein S6
(S6RP), pS6RP (Ser240/244), glycogen synthase (GS),
pGS (Ser641), Akt, pAkt (Ser473), GSK-3β and GSK-3α.
These antibodies were obtained from Cell Signaling
Technology Japan (Osaka, Japan). β-actin was used as a
loading control and anti-β-actin was obtained from
Abcam Inc. (Cambridge, MA, USA).
Protein kinase assays
Kinase assays were performed for 30 min at 30 °C with
0.5 μL of recombinant GSK-3β (NEB) and 0.5 μg of re-
combinant GST-4EBP1 in kinase buffer (50 mM Tris–
HCl, 50 mM NaCl, 5 mM dithiothreitol, 1 mM ethylene-
diaminetetraacetic acid (EDTA), 50 % glycerol, and
0.03 % Brij 35, pH 7.5) containing 500 μM ATP in the
presence and absence of 25 μM AR-A014418 or SB-
216763. The reaction products were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, and
immunoblot analysis was performed.
Cell proliferation assay
ACHN, Caki1, and A498 RCC cells were cultured at 24,
48, and 72 h in the presence and absence of an
mTORC1 or GSK-3 inhibitor. The cell viability was esti-
mated using CellTiter 96 Aqueous One Solution Cell
Proliferation Assay (Promega, Madison, WI, USA) as de-
scribed previously [21]. Values of the half maximal in-
hibitory concentration (IC50) were calculated by fitting
concentration-response curves to a four-parameter logis-
tic sigmoidal function model using R package ‘drc’
(http://www.bioassay.dk). Synergistic, additive, or antag-
onistic effects of AR-A014418 and rapamycin combin-
ation treatment were determined based on the theorem
of Chou and Talalay [26], using a free software Compu-
Syn (www.combosyn.com,). The dose–effect relation-
ships for single agents and their combinations were
analyzed, and the combination index (CI) values were
calculated for each dose and the corresponding effect
level, designated as the fraction affected (Fa) meaning
the inhibited fraction of cell proliferation after drug ad-
ministration. For graphical presentation of drug inter-
action, a Fa-CI plot was constructed by simulating CI
values with CompuSym over a range of Fa levels from
0.05 to 0.97. The CI values provide a quantitative defin-
ition for an additive effect (CI = 1), synergism (CI < 1),
and antagonism (CI > 1) in drug combinations.
Cell cycle analysis
After treatment with AR-A014418 or rapamycin, ACHN
cells were harvested with trypsin-EDTA, centrifuged into
a pellet, and rinsed with phosphate-buffered saline
(PBS). Then, 80 % ethanol was added, and the cells were
incubated on ice for 1 h. The cells were washed with
PBS, re-suspended in PBS containing 20 μg/mL RNase
and 50 μg/mL propidium iodide (Sigma-Aldrich Japan),
and incubated at 37 °C for 1 h. The cells were analyzed
using the FACSCanII flow cytometry (Becton-Dickinson,
San Diego, CA, USA).
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Statistical analysis
Continuous variables are presented as the mean ± stand-
ard deviation (SD) for bar-charts and as the mean ±
standard error (SE) for concentration-response plots.
They were statistically analyzed using analysis of vari-
ance (ANOVA) and, if necessary, a post-hoc Bonferroni
test for multiple comparisons. P < 0.05 was considered
statistically significant. All analyses were performed
using R statistical software version 3.1.0 (http://cran.r-
project.org/).
Results
GSK-3 inhibition shows different modes of anti-
proliferative action in ACHN cells
We investigated cell proliferation in ACHN RCC cells
treated with inhibitors of mTORC1 or GSK-3. Treat-
ment of rapamycin and its derivative everolimus, both of
which are inhibitors of mTORC1, reduced cell viability,
and the ACHN cell viability leveled off when the con-
centrations of the rapalogues were higher than 10 nM
(Fig. 1a and b). By contrast, AR-A014418 and SB-
216763, both of which are ATP-competitive and small-
molecule inhibitors of GSK-3 [27, 28], decreased cell via-
bility in a concentration-dependent manner (Fig. 1c and
d). We further investigated the cell proliferation of hu-
man RCC cell lines (ACHN, Caki1 and A498) using in
detail-concentration of AR-A014418 and rapamycin
(Additional file 1: Figure S1). Generally, all the three cell
lines were less sensitive to rapamycin than AR-A014418,
not having reached 50 % inhibition of cell viability from
baseline even at high doses of rapamycin (1000 nM),
whereas the cell lines showed a dose-dependent decrease
in proliferation with IC50 between 27 and 45 μM treated
with AR-A014418 (Additional file 1: Figure S1). Rapamy-
cin caused G0/G1 arrest in ACHN cells without indu-
cing apoptosis (Fig. 1e). Similar to our previous study
[14], AR-A014418 induced apoptosis in conjunction with
the increase in the subG1 phase at 48 h (Fig. 1f ). Using
immunoblotting, we confirmed that GSK-3 inhibition
with AR-A014418 induced dose- and time-dependent
apoptosis, as measured by poly ADP ribose polymerase
(PARP) cleavage and reduction of XIAP (data not
shown). In contrast, AR-A014418 also reduced the G0/
G1 phase at 24 h independently of the increase in the
subG1 phase, implicating the possibility of anti-mitotic
action that is independent of apoptosis (Fig. 1f ).
Pharmacological and genetic inhibition of GSK-3 prevents
the downstream phosphorylation of mTORC1
To examine the role of GSK-3 in the mTORC1
downstream signaling pathway and its effects on cell
proliferation, we treated ACHN, Caki1, and A498 human
RCC cells, with AR-A014418, an ATP-competitive and
small-molecule inhibitor of GSK-3 [27], and examined its
effects on the phosphorylation of 4EBP1, S6K, and S6RP
(Fig. 2a). Immunoblot analysis showed that p4EBP1 at
Thr70, Thr37/46, and Ser65 were suppressed with treat-
ment of AR-A014418 in all the three cell lines. In parallel,
AR-A014418 simultaneously inhibited the phosphorylation
of S6K at Ser371 and its downstream substrate pS6RP at
Ser240/244. Treatment with two other GSK-3 inhibitors,
SB-216763 (ATP-competitive) [28] and TDZD8 (ATP-non-
competitive) [29], also reduced p4EBP1 and pS6RP levels
in ACHN cells (Fig. 2b). GSK-3 has a primary role in the
phosphorylation of glycogen synthase (GS), and it is known
to directly phosphorylate S6K at Ser371 in vitro. [30] Here,
we found that AR-A014418 induced dose- and time-
dependent inhibition of GSK-3 activity, as measured by
pGS at Ser641 and pS6K at Ser371 levels (Fig. 2a).
Next, to determine which of two GSK-3 isoforms,
GSK-3α and GSK-3β, phosphorylates 4EBP1, we ex-
amined p4EBP1 status in stable GSK-3α and GSK-3β
knockdown cells with siRNAs, respectively (Fig. 2c).
As expected, 4EBP1 phosphorylation at Thr70, Thr37/
46 and Ser65 in siGSK-3β-transfected ACHN cells de-
creased than negative controls. However, siGSK-3α
knockdown presented with inconsistent outcome, no
changes and reduction in p4EBP1 for each of two
specific siGSK-3α transfected, respectively (Fig. 2c).
Compared with the human renal proximal tubular epi-
thelial cells (HRPTEpC) and the normal renal paren-
chymas, the mTORC1 downstream pathway was
strongly activated in the RCC cell lines (Fig. 2d). These
results indicate that GSK-3β, rather than GSK-3α, is re-
quired to maintain 4EBP1, S6K, and S6RP phosphoryl-
ation in RCC cells.
GSK-3 regulates 4EBP1 and S6RP phosphorylation
differently from PI3K/Akt/mTORC1 pathway
To investigate the relationship GSK-3 and mTORC1 path-
way further, we next examined the effect of AR-A014418
and rapamycin on phosphorylation of 4EBP1 and S6RP, the
downstream signaling targets of mTORC1. The phosphor-
ylation levels of 4EBP1 and S6RP in ACHN cells decreased
rapidly at 30 min after exposure to AR-A014418, and the
phosphorylation remained suppressed through 48 h
(Fig. 3a, left). In contrast, rapamycin temporarily sup-
pressed 4EBP1 phosphorylation at Thr70 from 2 to 12 h
and at Thr37/46 and Ser65 from 4 to 12 h, but did not pre-
vent phosphorylation at Thr37/46, Thr70 and Ser65 at 24
and 48 h. S6RP phosphorylation was partially suppressed
from 0.5 to 12 h, and were finally restored at 24 and 48 h
as well as p4EBP1 (Fig. 3a, right). Similar to rapamycin,
LY294002, a PI3K/Akt/mTORC1 inhibitor, moderately at-
tenuated p4EBP1 at Thr70 and Ser65 without apparent
changes at Thr37/46 phosphorylation. As expectedly,
LY294002 also inhibited pAkt and pS6RP simultaneously
(Fig. 3b). To our investigation, the effect of AR-A014418
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Fig. 1 (See legend on next page.)
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on Akt phosphorylation at Ser473 varied according to the
concentrations and RCC cell lines (Additional file 2: Figure
S2). However, p4EBP1 commonly decreased in ACHN,
Caki1, and A498 cells following AR-A014418 treatment
(Fig. 3a and Additional file 2: Figure S2).
These results support that GSK-3 regulates the phos-
phorylation of 4EBP1 directly and S6K differentially in a
manner independent of the PI3K/Akt/mTORC1 path-
way. In addition, it reflects that 4EBP1 would take phos-
phorylation differentially at Thr70, Thr37/46 and Ser65.
GSK-3β could directly phosphorylate 4EBP1
We performed an in vitro kinase assay using recombin-
ant proteins of GSK-3β and 4EBP1 (Fig. 4). Recombinant
GSK-3β phosphorylated recombinant 4EBP1 at Thr70,
Thr37/46, and Ser65. AR-A014418 and SB-216763
blocked the recombinant GSK-3β mediated phosphoryl-
ation of recombinant 4EBP1. These results suggest that
GSK-3β could participate in the direct phosphorylation
of 4EBP1 at Thr70, Thr37/46, and Ser65, as reported for
S6K [30].
Fig. 2 Pharmacological and genetic inhibition of GSK-3 suppresses 4EBP1, S6K, and S6RP phosphorylation in the mTORC1 downstream signaling
cascade aberrantly activated in RCC cell lines. a The human RCC cell lines ACHN, Caki1, and A498 cells were treated with AR-A014418 (25 μM or
50 μM) for 24 h or 48 h, respectively. b ACHN cells were treated with SB-216763 (25 μM or 50 μM), and with TDZD8 (5 μM or 10 μM) for 24 h or
48 h, respectively. c ACHN cells were transfected with non-specific control siRNA (50 nM) as negative control (NC), GSK-3β-targeting (siGSK3β)
siRNAs (25 nM or 50 nM) and GSK-3α-targeting (siGSK3α) siRNAs (50nM) for 48 h after seeding. d Human renal proximal tubular epithelial cell
(HRPTEpC) and normal kidney tissues had slight expression of GSK-3 and the mTORC1 downstream substances (p4EBP1, pS6K and pS6RP). In
contrast, GSK-3 and the mTORC1 downstream signaling pathway were strongly activated in RCC cells. In a–d, immunoblot analysis was performed
after cell lysis. Data are representative of at least three separate experiments
(See figure on previous page.)
Fig. 1 Differences in the suppressive effects of mTORC1 and GSK-3 inhibitors on cell proliferation. a–d Relative cell viability was measured by an
MTS assay in ACHN cells treated with rapamycin (a), everolimus (b), AR-A014418 (c), and SB-216763 (d) at the indicated concentrations at 24, 48,
and 72 h, respectively. Data are the mean ± SD in each bar-plot from six replicates of each cell line. e and f Cell cycle distribution in the presence
of 100 nM of rapamycin (e) or 25 μM AR-A014418 (f) at 24 and 48 h. Data are representative of at least three independent experiments
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Biphasic response to drug combination of GSK-3 and
mTORC1 inhibitors in a concentration-dependent fashion
In ACHN cells, we investigated cell proliferation with
single agents and a combination of GSK-3 inhibitor (AR-
A014418) and mTORC1 inhibitor (rapamycin) using the
MTS assay. Different concentration in the combination
was kept at a constant dilution ratio of 25,000 : 1. The
dilution ratio was determined on IC50 values from
concentration-response relation in MTS assay at 72 h
for the single agents (Fig. 5a) [26]. The combination ef-
fects were determined as the combination index with
CompuSyn software (Fig. 5b) [26]. The combination
effects were additive at lower concentrations, but more
antagonistic at higher concentrations.
GSK-3 regulates cell proliferation and p4EBP1
independently of chemoresistance to rapamycin
To confirm that GSK-3 regulates cell proliferation and
4EBP1 phosphorylation independently of PI3K/Akt/
mTORC1 pathway, we furthermore investigated inhibi-
tory effects of AR-A014418 in rapamycin-resistant
ACHN (ACHN/RR) cells that were generated through
culturing ACHN parental (ACHN/P) cells in progres-
sively higher concentrations of rapamycin from 1nM
Fig. 3 GSK-3 differentially regulates 4EBP1 and S6RP phosphorylation in ACHN cells. a Changes in the phosphorylation levels of 4EBP1 and S6RP
over time after treatment of AR-A014418 (25 μM) or rapamycin (100 nM) to ACHN cells. b ACHN cells were treated with LY294002 (10 μM) for the
indicated times. In a and b, the cells were lysed and then analyzed for the phosphorylation of 4EBP1 and S6RP by immunoblotting. Data are
representative of at least three independent immunoblot experiments
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finally to 1 μM. As shown in Fig. 6a, ACHN/P cells were
sensitive to rapamycin in proliferation, but ACHN/RR
cells presented with rapamycin-resistance. In contrast,
AR-A014418 suppressed greatly ACHN/P and ACHN/
RR proliferation in concentration-dependent manner.
Notably, the concentration-response relation for AR-
A014418 did not differ from ACHN/P and ACHN/RR
cells (Fig. 6b). In ACHN/RR cells, AR-A014418 remark-
ably inhibited p4EBP1 and pS6RP rapidly and the inhib-
ition had continued constantly even at 48 h. However,
phosphorylations of 4EBP1 and S6RP in ACHN/RR cells
were suppressed only mildly and transiently by
rapamycin. The phosphorylations almost recovered to
the baseline in 24 h (Fig. 6c). The findings indicate that
GSK-3 inhibition can sufficiently decrease the activities
of mTORC1 downstream cascades and overcome
rapamycin-resistance in RCC cells.
Discussion
Consistent with previous reports [30, 31], in the present
study, we demonstrate that GSK-3β directly phosphory-
lates 4EBP1 independent of rapamycin sensitivity to
mTORC1 and continuously activates 4EBP1 and S6K,
the mTORC1 downstream substrates to drive cell prolif-
eration in RCC cell lines. The present findings would
also indicate that the direct GSK-3β/4EBP1 pathway is
an important subcellular mechanism as an inherent
equipment for RCC cells to acquire clinical chemoresis-
tance to mTORC1 inhibitors. Although rapamycin in-
creased the G0/G1 phase in cell cycle and suppressed
cell proliferation, the inhibitory effects of rapamycin on
the mTORC1 downstream pathway were only transient
leading to gradual return of p4EBP1 and pS6RP to the
baseline level. When the present results extrapolated
into clinical setting, it could be easy for us to understand
limited efficacy of mTORC1 inhibition on size reduction
and progression of RCC [2, 3]. Our data suggest that
GSK-3 inhibition could be a promising strategy for the
treatment of mRCC.
GSK-3 in solid cancers have two opposite functions in
different types of tumor cells, a suppressor (e.g., some
skin and breast cancers) or promoter (e.g., colon, liver,
ovarian and pancreatic tumors) [17–19, 32]. However,
the underlying mechanisms to regulate the differenti-
ation between the opposite roles of GSK-3 remain un-
solved [32]. To date, we have reported that GSK-3β is
highly expressed in tumor nuclei of RCC [21]. In human
Fig. 4 In vitro kinase assays. In vitro kinase assays were performed
using recombinant GSK-3β and recombinant 4EBP1 as described in
the Materials and methods. Either AR-A014418 (25 μM) or SB-216763
(25 μM) was applied in vitro to inhibit recombinant GSK-3β. p4EBP1
levels were measured with immunoblot analysis. Data are representative
of three separate immunoblot analysis
Fig. 5 Combination effects of AR-A014418 and rapamycin in ACHN cells. a ACHN cells were treated with AR-A014418 and rapamycin as single agents or
their combination at different concentration at a constant dilution ratio of 25,000 : 1. Cell viability was assessed using MTS assay after 72 h incubation. Data
are the mean ± SD in each bar-plot from four replicates of ACHN cells at each concentration. b Effects of the drug combination was demonstrated on
a Fa-CI plot generated using CompuSyn. Combination index (CI) determines the type of drug interaction as follows: additive, synergistic, or antagonistic
if CI is 1, < 1 or > 1, respectively [26]. The combination effects varied from additivity to antagonism according to the increase in drug concentration
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RCC specimens, aberrant GSK-3β overexpression that is
negatively regulated by miR-199 [21] was observed in 68
out of 74 (92 %) cases, suggesting clinical relevance of
RCC biology [20]. Using RCC cell lines, we have re-
vealed that inhibition of GSK-3 results in decreased ex-
pression of NF-kB target genes Bcl-2 and XIAP leading
to a subsequent increase in RCC apoptosis and the anti-
tumor effect of sorafenib, TKI available for treatment of
mRCC in clinical practice [20, 22]. According to a recent
review [32], possible differences in apoptotic, Wnt/β-ca-
tenin, and NF-kB signaling pathways among various
types of cancer may be related to the opposite effects of
GSK-3 on tumor proliferation.
Drug combination of AR-A014418 and rapamycin in
MTS assay for ACHN proliferation presented with addi-
tivity at lower concentrations, but antagonism at higher
concentrations. The biphasic aspect, including the tran-
sition from additive to antagonistic, with increasing drug
concentration indicated the presence of at least two
regulatory pathways from GSK-3 to 4EBP1. The additive
effect is considered to reflect a direct pathway inde-
pendent of the PI3K/Akt/mTORC1 cascade. The an-
tagonism at higher concentrations could possibly be
competitive inhibition because GSK-3 and mTORC1
in combination share 4EBP1 and S6K as target substrates
(Figs. 2, 3 and 6c).
4EBP1 plays an important role in cell proliferation by
selectively translating mRNAs that encode various pro-
teins promoting cell cycle and proliferation [8]. Phos-
phorylation, mainly at sites Thr37, Thr46, Ser65, and
Thr70, causes 4EBP1 to dissociate from eIF4E, allowing
for cap-dependent translation [33, 34]. It is widely
accepted that mTORC1 is a main regulator of 4EBP1 to
keep cellular homeostasis [35]. However, as shown in
Fig. 2d, 4EBP1 and S6RP expression and phosphoryl-
ation aberrantly increased in RCC cells but not in nor-
mal kidney tissues and a renal tubular cell line,
suggesting that GSK-3 as well as mTORC1 could be in-
volved in the activation of mTORC1 downstream path-
way in RCC. Moreover, rapamycin and LY294002 only
partially inhibited the phosphorylation of 4EBP1 (Fig. 3a
and b) [15]. Not only pharmacological but also genetic
inhibition of GSK-3β with specific siRNAs sufficiently
decreased phosphorylation of mTORC1 downstream
substrates in RCC cell lines (Figs. 1 and 2). Therefore,
we here provide the evidence that GSK-3β can directly
phosphorylate 4EBP1 at Thr37/46, Thr70, and Ser65,
possibly in sequential order (Fig. 4). In particular,
p4EBP1 was rapidly inhibited following AR-A014418
treatment at 30 min in ACHN cells (Fig. 3a) and within
1 h in acquired rapamycin-resistant ACHN cells (Fig. 6c),
supporting the direct involvement of GSK-3β in 4EBP1
phosphorylation in RCC cells.
Approximately 100 substrates of GSK-3 have been
identified to date [17, 19]. Recently, several researchers
reported about relationships between GSK-3β and Akt/
mTORC1/4EBP1 pathway [31, 36–38]. However, to our
knowledge, only two papers have referred to direct inter-
action of GSK-3β and 4EBP1 currently [31, 38]. Accord-
ing to Shin et al. [31], GSK-3β directly phosphorylates
4EBP1 at Thr37/46 and inactivates 4EBP1 activity in
breast cancer and normal cell lines, thereby increasing
eIF4E-dependent protein synthesis and regulating cell
proliferation. In addition, they showed that GSK-3β
Fig. 6 GSK-3 inhibition overcomes rapamycin-resistance in ACHN cells. ACHN/P (parental) and ACHN/RR (rapamycin-resistant) cells were treated
with increasing doses of rapamycin (a) and AR-A014418 (b) at 72 h. Cell viability was measured using MTS assay. Data are the mean ± SE in each
from six replicates of each cells. In a and b, significant interaction between the main effects of cell lines (ACHN/P or ACHN/RR) and drug concentrations
was statistically detected with two-way ANOVA (p < 0.05). As for the simple main effect, the difference in cell lines (ACHN/P or ACHN/RR) was
statistically significant for rapamycin and not significant for AR-A014418 (one-way ANOVA with Bonferroni test; p < 0.05 and = 0.71, respectively).
c ACHN/RR cells were treated with AR-A014418 (25 μM) or rapamycin (100 nM) at indicated times. The cells were lysed and analyzed for the
phosphorylation of 4EBP1 and S6RP by immunoblotting. Data are representative of at least three separate immunoblot experiments
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significantly reduced in vivo the size of tumor injected
subcutaneously in a mouse xenograft model [31].
Many GSK-3β substrates have the motif Ser/Thr-Pro-
X-X-pSer/Thr [39]. The binding affinity of GSK-3β to a
substrate is enhanced if the substrate receives prior
phosphorylation at the second Ser/Thr [19]. 4EBP1 re-
portedly has seven phosphorylation sites (Thr37/46,
Ser65, Thr70, Ser83, Ser101, and Ser112) [14, 39]. Com-
parison of the 4EBP1 sequence with those of known
GSK-3β substrates showed that the best-matched se-
quences in 4EBP1 for phosphorylation by GSK-3β are
Thr-Pro-Gly-Gly-Thr for both Thr37 and Thr46 as the
first Ser/Thr residues [40]. Phosphorylation of 4EBP1 at
Thr37/46 by GSK-3β requires pre-phoshorylation at
priming sites (Thr41/50) [31]. However, GSK-3 does not
necessarily require a primed substrate [17, 19, 41]. The
residues other than Thr37/46, Thr70, and Ser65 in
4EBP1 might be also targeted by GSK-3β. In the present
study, we demonstrated that recombinant GSK-3β phos-
phorylated an unprimed recombinant 4EBP1 at Thr37/
46. It is possible that phosphorylation of Thr41/50 also
is regulated by GSK-3β itself. There are no priming
phosphorylation sites at Thr70 and Ser65 of 4EBP1
(Thr70-Pro-Pro-Arg-Asp, Ser65-Pro-Val-Thr-Lys). The
phosphorylation of 4EBP1 appears to occur in a hier-
archical manner, as follows [13, 14]: Thr37/46 are phos-
phorylated at baseline, and this is further enhanced by
insulin production [13, 14]. Thr37/46 phosphorylation is
followed by phosphorylation of Thr70, followed by phos-
phorylation of Ser65 as the last step [13]. Phosphoryl-
ation of Thr70 seems to play the most important role in
releasing 4EBP1 from eIF4E [14]. The fact that the phos-
phorylation levels of recombinant unprimed 4EBP1 in-
creased in the order of Thr37/46, Thr70, and Ser65
likely reflects this hierarchical phosphorylation process
(Fig. 4). As shown in Fig. 3, LY294002 and rapamycin
exhibited apparently no and slightly inhibitory action on
Thr37/46 phosphorylation in 4EBP1, respectively, lead-
ing to the notion that Thr37/46 residue may be the main
target of GSK-3 in case of 4EBP1 phosphorylation [31].
Abnormal overexpression of GSK-3 is observed in can-
cers which are resistant to chemo-, radio- and targeted
therapy [32]. Targeting GSK-3 could improve cancer
therapy and overcome therapeutic resistance [32].
The mechanism by which GSK-3 inhibition results in
fluctuations of pAkt at Ser437 over time is currently un-
clear (Additional file 2: Figure S2). One potential mech-
anism is that at the early phase, inhibition of GSK-3β by
AR-A014418 results in the hypo-phosphorylation of
Ser1235 of rictor, a component of mTORC2 that acti-
vates Akt via pSer437 [42]. Another possibility is that
S6K could participate in negative feedback regulation to
affect the phosphorylation of rictor at Thr1135 through
the insulin receptor substrate 1/PI3K axis [6, 43]. A third
potential mechanism could involve apoptosis-induced
protein degradation and the consequent reduction of
pAkt [5, 6]. Although GSK-3 inhibition appears to in-
duce variable reactions of pAkt at Ser473 with unknown
mechanisms, it consistently suppressed 4EBP1 and
mTORC1 downstream signaling in RCC cells in the
present study. In their report, Armengol et al. [10] stated
that 4EBP1 would act as a key molecular funnel factor in
carcinogenesis of various types of human cancers, re-
gardless of the upstream oncogenic alterations. The re-
sults of the present study on RCC cells seem to support
this hypothesis.
Conclusions
GSK-3β could directly phosphorylate 4EBP1 and activate
the mTORC1 downstream signaling cascades to enhance
protein biosynthesis and cell proliferation in RCC cell
lines independent of rapamycin sensitivity. The direct
GSK-3β/4EBP1 pathway, not associated with the PI3K/
Akt/mTORC1 pathway, would be an important subcel-
lular intrinsic mechanism for RCC cells to resist
mTORC1 inhibition, possibly leading to potential thera-
peutic limitations in systemic treatment for mRCC pa-
tients with rapalogues.
Additional files
Additional file 1: Figure S1. Differences in suppressive effects of
mTORC1 and GSK-3 inhibitors on cell proliferation. Relative cell viability
was measured by an MTS assay in ACHN, Caki1 and A498 cells treated
with rapamycin (A), and AR-A014418 (B) at the indicated concentrations
at 72 h. A498 cells, highly insensitive to rapamycin, did not reach maximal
inhibitory effect even at 10 μM rapamycin, with IC50 not assessable (NA).
Data are the mean ± SE from six replicates of each cell line. In (A) and (B),
significant interaction between cell lines and drug concentrations was
statistically detected with two-way ANOVA (p < 0.05). As for the simple
main effect, the difference in cell lines (ACHN, Caki1 or A498) was
statistically significant for rapamycin (one-way ANOVA; p < 0.05, Bonferroni
test; p < 0.05 for ACHN vs. Caki1 and A498) and not significant for
AR-A014418 (one-way ANOVA; p = 0.47). (PPTX 60 kb)
Additional file 2: Figure S2. Different effects of GSK-3 inhibition on Akt
and 4EBP1 phosphorylation. (A) ACHN cells were treated with AR-
A014418 (25 μM) or rapamycin (100 nM) for the indicated times. Cells
were lysed and analyzed for pAkt by immunoblotting. (B) Caki1 and A498
cells were treated with AR-A014418 at 25 μM or 50 μM for 24 h or 48 h,
respectively. Immunoblotting was performed after cell lysis. In (A) and (B),
Data are representative of at least three separate immunoblot analyses.
(PPTX 107 kb)
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